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pen access Abstract Background: Midazolam plays a major role in sedation and large doses might be used
under certain circumstances. Trans-vaginal oocyte retrieval is one of the most painful procedures
in which monitored anesthesia care (MAC) is needed. The mechanism by which midazolam exerts
anti-aggregation of human platelets is still unclear.
This work aimed to investigate the in vivo suppressing effect of midazolam on human platelet aggre-
gation.
Methods: Sixty adult females ASA I–II, scheduled for trans-vaginal ultrasound oocyte retrieval by
combined intravenous midazolam sedation with paracervical local nerve block were included. At
the end of the procedure, it was found that the range of total midazolam consumption was 4.9–
9 mg. Thereby, patients were divided into three groups according to the total consumption of
midazolam: Group I (4.9–6.2 mg), Group II (6.3–7.6 mg), Group III (7.7–9 mg). Patients who
needed other drugs for sedation were excluded. Pre- and post-operative Bleeding Time (BT) were
recorded. Two blood samples were collected from each patient to test the inhibitory effect of midaz-
olam on platelet aggregation. Platelet aggregation was tested using platelet-aggregometer. ELISA
was used to measure thromboxane B2 formation. Flowcytometry was used to evaluate whether329364.
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Anesthesiologists. Production
an Society of Anesthesiologists.
lsevier
under CC BY-NC-ND license.
4 S.H. Waly et al.glycoprotein IIb–IIIa complex is the receptor site for the antiplatelet action of midazolam.
Results: Only 51 patients completed the study: Group I (n= 16), Group II (n= 24), and Group
III (n= 11). Bleeding Time (BT) showed signiﬁcant prolongation in group III compared to basal
levels. Midazolam suppressed platelet aggregation in a dose-dependent manner as detected by
aggregometer. Glycoprotein IIb–IIIa complex is not its site of action as shown by ﬂowcytometric
analysis. Lastly, thromboxane B2 was signiﬁcantly inhibited by midazolam.
Conclusion: This study revealed that midazolam dose-dependently inhibits platelet aggregation by
a mechanism not involving the binding of glycoprotein IIb–IIIa complex (ﬁbrinogen receptor). It
was also found that midazolam inhibits thromboxane A2 formation.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
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Midazolam is a benzodiazepine derivative that is widely used
in anesthetic practice. It is a familiar agent during monitored
anesthesia care (MAC) [1].
Despite that the anti-aggregatory effect of benzodiazepine
derivatives remains unclear [2], many precious studies
explained the inhibitory effect of benzodiazepines on platelet
aggregation via inhibiting the binding of platelet-activating
factor to platelets (triazolam and alprazolam) [3] or interfering
with arachidonate-induced aggregation (clonazepam, diaze-
pam, and ﬂumazenil) [4]. Other studies explained the antiag-
gregatory effect of benzodiazepines derivatives by inhibition
of lipid peroxidation (gidazepam and phenazepam) [5]. The
mechanism by which midazolam inhibits platelet aggregation
is still unclear [6].
Trans-vaginal ultrasound-guided oocyte retrieval represents
one of themost painful (despite vital) maneuvers during the pro-
cess of in vitro fertilization (IVF) [7].Different sedative and anes-
thetic techniques have been described for calming the patient
and controlling her pain during oocyte retrieval [8]. One of these
techniques is theMAC, which is a technique that is explained by
the American Society of Anesthesiologists (ASA) as a planned
procedure during which the patient undergoes local anesthesia
together with sedation and analgesia [9]. The level of sedation
during this procedure varies from light (patient just feels very re-
laxed), to heavy (patient is unaware and only rouses to signiﬁ-
cant stimulation). The commonest anesthetic agents to be used
for providingMACare propofol,midazolam, and/or remifenta-
nyl due to its favorable pharmacodynamics and pharmacokinet-
ics [9].
The present study was designed to use midazolam as a sole
intravenous drug combined with paracervical local nerve block
in patients under monitored anesthesia care for ultrasound
guided trans-vaginal oocyte retrieval. The aim of our work
was to study the in vivo anti-aggregatory effect of midazolam
on human platelets.
2. Patients and methods
After local ethics committee approval and an informed written
patient consent, 60 adult females classiﬁed according to Ameri-
can Society of anesthesiologists as ASA I–II (aged between 20
and 40 years), scheduled for trans-vaginal ultrasound oocyte re-
trieval (via combined intravenousmidazolam sedationwith par-
acervical local nerve block), have been included in the current
study. Exclusion criteria included: refusal of the patient, respira-
tory impairment where arterial O2 saturation (SaO2 < 92%) onroom air, impaired renal (creatinine > 1.5 mg/dl) or hepatic
function (serum bilirubin > 1.5 mg/dl or doubled AST), coag-
ulopathies (platelet count < 100 · 103/ll, BT < 3 min), and
those who had taken any medications during the preceding
2 weeks (as the presence of chylomicra or drugs may disturb
aggregation battern).
For all patients, pre-operative and post-operative Bleeding
Time (BT normal levels = 1–3 min) were recorded.
A dose of 0.06–0.1 mg/kg midazolam was administered to
achieve a Ramsay sedation score [11] (RSS) of 5. RSS has
six levels according to patient response: (1) anxious and/or agi-
tated; (2) cooperative, oriented and tranquil; (3) responds to
commands only; (4) brisk response to light, glabellar tap or
loud auditory stimulus; (5) sluggish response to light, glabellar
tap or loud auditory stimulus and (6) no response.
Patients who reached the maximum dose of sedation of
midazolam without achieving the targeted RSS were excluded
from the study and were given 1 mg/kg propofol.
Paracervical local nerve block was performed by the gyne-
cologist to block the inferior hypogastric plexus and ganglia by
injecting of the local anesthetic (lidocaine 0.5 mg/kg in 20 ml
saline) into the lateral fornices of the vagina after performing
syringe aspiration to exclude inadvertent intravascular injec-
tion [7].
All patients were allowed to breath O2 100% spontaneously
via transparent face mask and were closely monitored by
attendant anesthesiologist, ECG, non-invasive blood pressure
measurement, and pulse oximetry.
Only 51 patients completed the study (nine were excluded
due to inadequate overall intraoperative RSS and propofol
injection was needed).
At the end of the procedure, it was found that the range of
total midazolam consumption was 4.9–9 mg (the lowest dose
of midazolam used was 4.9 mg, while the highest dose was
9 mg). Patients were then divided into three groups according
to the total consumption of midazolam: Group I (4.9–6.2 mg);
Group II (6.3–7.6 mg) and Group III (7.7–9 mg). It was then
found that Group I included 16 patients, Group II included 24
patients, while Group III included 11 patients.
2.1. Preparation of human platelet suspensions
Two blood samples were collected from the patient in the same
way pre-operatively [before givingmidazolam (basal)] and post-
operatively [3 min after injecting the last dose of midazolam].
Ten mililiter of venous blood sample was collected without
stasis and anticoagulated with 1 volume of sodium citrate,
38 g/L, pH 7.4, to 9 volumes of blood.
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whole blood by 20-min centrifugation at 100 g at room tem-
perature; platelet-poor plasma (PPP) was prepared by further
centrifugation at 2000 g for 10 min.
2.2. Platelet aggregation
Platelet-aggregometer (PA-200 instrument, Japan) was used to
detect platelet aggregation. Pre-warming of (0.4 ml) of platelet
suspensions was done at 37 C for 2 min. A platelet-aggrega-
tion inducer (collagen 2 lg/ml) was added (Sigma Chemical
Co.). The reaction was allowed to stand for at least 6 min.
The extent of aggregation of platelets at the end of the opera-
tion was expressed as a percentage of the basal aggregation.
2.3. Analysis of the platelet surface glycoprotein IIb–IIIa
complex using ﬂow cytometry
Fluorescein isothiocyanate conjugated triﬂavin (FITC-triﬂavin)
is a speciﬁc ﬁbrinogen receptor antagonist [10]. This technique is
based upon the idea that if midazolam binds to ﬁbrinogen recep-
tor (glycoprotein IIb–IIIa complex), the FITC-conjugated tri-
ﬂavin will not be able to bind to the receptor. This will result
in no increase in ﬂuorescence intensity.While if midazolam does
not bind to the receptor (i.e., it is not the site of antiplatelet effect
of midazolam), the ﬂuorescence intensity will rise as a result of
binding of FITC-conjugated triﬂavin to the ﬁbrinogen receptor.
The ﬁnal concentration of FITC- triﬂavin (US Biological,
Swampscott, Massachuse-tts, USA) was adjusted to 1 mg/ml.
2 ll of FITC-triﬂavin was added to aliquots of platelet suspen-
sions 200 lg (4 · 108/ml). The suspensions were incubated for
5 min, and the volumewas adjusted to 1 ml/tubewith phosphate
buffered saline solution. The suspensions were then assayed
using a ﬂow cytometer (FACscan Calibur; Bectopn Dickinson,
San Jose, CA) for ﬂuorescein-labeled platelets. Data were col-
lected from 50.000 platelets for each patients group.
2.4. Detecting thromboxane B2 formation
Thromboxane B2 is the stable metabolite of T · A2, released
during aggregation. Collagen (2 lg/ml) was added to human
platelet suspensions (4 · 108/ml) for all groups. 6 min later,
2 mM EDTA and 50 lM indomethacin were added to the
reaction suspensions. The vials were then centrifuged for
3 min at 14,000 rpm. The thromboxane B2 concentrations of
the supernatants were measured using an enzyme immunoas-
say kit (R&D Minopllas, USA).
2.5. Statistical analysis
Sample size was calculated (n= 60) by using a pilot study to
determine patients scheduled for trans-vaginal ultrasound oo-
cyte retrieval in 1 month then the whole patients (whole popu-
lation) for 1 year was calculated. Power of the study was 80%,
conﬁdence interval was 95%, and level of signiﬁcance was
determined at 5% (P< 0.05).
Data were checked, entered and analyzed using SPSS version
11. Data were expressed as mean ± standard deviation for
parametric results, as number for qualitative one, or as percent-
age. ANOVA, paired t-test, chi-square (v2) or Krunskal–Wallis
test were used when appropriate. P< 0.05 was considered
signiﬁcant.3. Results
There were no statistical signiﬁcant differences in demographic
data (age and weight), or the duration of the procedure be-
tween the three groups (Table 1).
Bleeding Time (BT) showed signiﬁcant prolongation in
group III compared to basal levels (Table 2).
3.1. Effect of midazolam on platelet aggregation in human
platelet suspensions
Midazolam suppressed collagen-induced platelet aggregation
in a dose-dependent manner. Midazolam at the concentration
of 7.2 mg inhibited platelet aggregation by 50%, i.e. the inhib-
itory concentration values of midazolam to 50% (IC50) for col-
lagen induced platelet aggregation, was about 7.2 (Fig. 1).
3.2. Results of ﬂow cytometry analysis of the platelet surface
glycoprotein IIb–IIIa complex
Triﬂavin is a substance that is puriﬁed from snake venom and
has antiplatelet activity. It is a speciﬁc antagonist to ﬁbrinogen
receptor that exerts its anti-platelet effect through direct inter-
ference with binding of ﬁbrinogen to its receptor (glycoprotein
IIb–IIIa complex) [10]. The binding of ﬁbrinogen to the glyco-
protein IIb–IIIa complex is the ﬁnal destination for agonist-in-
duced platelet aggregation [12]. In the present study we were
interested to ﬁnd out if midazolam binds directly to the ﬁbrin-
ogen receptors on platelet membrane, leading to inhibition of
platelet aggregation induced by agonist (collagen 2 lg/ml).
Themeanﬂuorescence intensity of (FITC)-triﬂavin (2 lg/ml)
bound directly to collagen (2 lg/ml) activated platelets was
90 ± 11, and it was signiﬁcantly reduced in the presence of
5 mM EDTA (negative control 70 ± 23). Effect of midazolam
was studied at two doses and it did not signiﬁcantly inhibit
FITC-triﬂavin binding to ﬁbrinogen receptor in platelet suspen-
sions at any dose: (a) at a concentration of 7 mg (94.6 ± 16.4)
and (b) at a higher concentration of 9 mg (92.3 ± 13.5). These
results suggest that midazolam’s inhibitory effect on platelet
aggregation is not through binding to ﬁbrinogen receptor (gly-
coprotein IIb–IIIa complex) (Fig. 2).
3.3. Effect of midazolam on thromboxane B2 formation
Resting platelets produced relatively little thromboxane B2
(47.3 ± 11.6) compared with collagen activated platelets
(259.2 ± 39.4).
Results obtained using various doses ofmidazolam indicated
that midazolam (4.9–9 mg) dose-dependetly inhibited throm-
boxane B2 formation in platelets stimulated by collagen (2 lg/
ml) (Table 3). Signiﬁcant inhibition of thromboxane B2 forma-
tion occurred with group I (172.8 ± 23.5), while highly signiﬁ-
cant inhibition occurred with groups II (126.4 ± 19.7) and III
(71 ± 11.2). These results indicate thatmidazolam has an inhib-
itory effect on thromboxane A2 formation.
4. Discussion
The results obtained in present study showed that midazolam
inhibited collagen-induced human platelet aggregation and
attenuated thromboxane A2 formation in a dose-dependent
Table 2 Bleeding time before and after the procedure.
Bleeding time
(min)
Basal 1.73 ± 0.02
Group I (n= 16) [midazolam= 4.9–6.2 mg] 1.91 ± 0.08
Group II (n= 24) [midazolam= 6.3–7.6 mg] 2.07 ± 0.03
Group III (n= 11) [midazolam= 7.7–9 mg] 2.6 ± 0.05*
Data were presented as mean ± SD.
* P< 0.05 considered signiﬁcant as compared to basal levels.
Table 1 Demographic data and duration of the procedure in the studied groups.
Age (years) Weight (kg) Duration of procedure (min)
Group I (n= 16) [midazolam= 4.9–6.2 mg] 26.3 ± 7.0 85.8 ± 4.1 17.5 ± 3.2
Group II (n= 24) [midazolam= 6.3–7.6 mg] 25.8 ± 5.9 86.7 ± 3.3 15.7 ± 4.7
Group III (n= 11) [midazolam= 7.7–9 mg] 26.1 ± 6.3 85.4 ± 3.7 16.3 ± 5.1
Data were presented as mean ± SD.
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Figure 1 The inhibitory concentration curve of midazolam for
collagen-induced platelet aggregation. Aggregation of collagen-
induced platelet was suppressed by 50% at the dose of 7.2 mg of
midazolam (IC50 = 7.2).
6 S.H. Waly et al.manner in patients under monitored anesthesia care for ultra-
sound guided trans-vaginal oocyte retrieval. It was also shown
thatmidazolamdoes not act through ﬁbrinogen receptor (glyco-
protein IIb–IIIa complex) on the platelets surface membrane.
Platelet aggregation may occur by at least two independent
but closely linked pathways. The ﬁrst pathway involves arachi-
donic acid metabolism. Activation of phospholipase enzymes
(PLA2) releases free arachidonic acid frommembrane phospho-
lipids. About 50% of free arachidonic acid is converted by lipo-
oxygenase enzyme to a series of products which are important
chemo-attractants of white cells. The remaining 50% of arachi-
donic acid is converted by the enzyme cyclo-oxygenase into la-
bile cyclic endoperoxides, most of which are in then converted
by thromboxane synthetase into thromboxane A2 [13].
The second pathway of platelet aggregation can proceed
completely independently from the ﬁrst one: various platelet
agonists including thrombin, thromboxane A2 and collagen
bind to receptors and via aG-proteinmechanism activates phos-
pholipaseC. That leads to activation of different regulatory pro-
teins and also for the liberation of arachidonic acid from
membrane phospholipids and the generation of thromboxaneA2. Thromboxane A2 is very labile with a half-life of less than
1 min before it is degraded into the inactive thromboxane
metabolite B2 and malonyldialdehyde [13].
Thromboxane A2 (TXA2) is synthesised by activated plate-
lets and it induces platelet aggregation by expressing the glyco-
protein complex GP IIb/IIIa in the cell membrane of platelets.
Fibrinogen attaches to these receptors resulting in further
strengthening the clot. Some of the dugs that possess antiplatelet
properties like aspirin irreversibly inhibit platelets by inducing
inhibition of thromboxane A2 formation. Because of his very
short half life, TXA2primarily functions as amediator in the tis-
sues close to the site of its production. In human studies,measur-
ing thromboxane B2 is used to indirectly measure TXA2
production [14,15]. In the present study, midazolam was found
to dose-dependently inhibit thromboxane A2 formation.
In the current study, Bleeding Time (BT) was signiﬁcantly
prolonged in group III compared to basal levels. However, such
prolongation did not exceed the high normal level of BT. These
results supports the previously obtained results by Rodgers and
Levin [16] which stated that there is no correlation between the
BT and defects in platelet adhesions; thus, BT is not useful for
detecting clinically signiﬁcant abnormalities in platelet
adhesion.
Glycoprotein IIb–IIIa is the principal receptor on the plate-
let plasma membrane. Fibrinogen and other agonists bind to
glycoprotein IIb–IIIa [17]. Bound ﬁbrinogen links platelets
together in an aggregate [18].
Midazolam sedation dose range between 0.01 and 0.1 mg/kg
[1]. Midazolam is a member of a generation of benzodiaze-
pines, called imadodiazepines. Adding imidazole ring to the
benzodiazepine nucleus resulted in its unique pharmacokinetic
properties [19].
The present study showed that midazolam has a dose-depen-
dent inhibitory effect on human platelet aggregation. The inhib-
itory concentration values of midazolam to 50% (IC50) for
collagen induced platelet aggregation, was achieved at a dose
of 7.2 mg in the current study. Results obtained by other studies
indicated that concentrations of (6–26 lM) midazolam used to
inhibit platelet aggregation in vitro had an (IC50 = 16.1 lM)
and claimed that these concentrations are close to those of blood
concentrations obtained during midazolam-induced sedation
in vivo [12]. The results obtained in that in vitro study was in
agreement with the results obtained in the current in vivo study.
Another study by Hsiao and his colleagues [2] (performed
both in vitro and in vivo) demonstrated that midazolam pos-
sesses anti-aggregatory effects that results in delayed latent
period of platelet formation which may signiﬁcantly inhibit
thrombus formation in vivo. This was in consistence with the
results obtained in the current study. In their study, Hsiao
and his colleagues [2] explained the antiplatelet activity of
midazolam by its inhibition of phospholipase C activation
and inhibition of intracellular Ca+2 mobilization in platelets.
Figure 2 Flowcytometric analysis of triﬂavin binding to human platelets in the absence or presence of different concentrations of
midazolam (7 and 9 mg): (A) the histogram represents the ﬂuorescence proﬁles of triﬂavin (2 lg/ml) in the absence of midazolam as a
positive control; (B) in the presence of EDTA (5 mM) as the negative control, (C) in the presence of a total given dose 7 mg and (D) 9 mg
midazolam respectively. Midazolam at the two studied doses did not inhibit FITC-triﬂavin binding to ﬁbrinogen receptor in platelet
suspensions suggesting that midazolam’s inhibitory effect on platelet aggregation is not through binding to ﬁbrinogen receptor.
Table 3 Effect of midazolam on thromboxane B2 formation
induced by collagen in washed human platelets in the three
studied groups.
Thromboxane B2 (ng/ml)
Resting 47.3 ± 11.6
Collagen (2 lg/ml) 259.2 ± 39.4*
Samples of Group I (n= 16)
+ Collagen (2 lg/ml)
172.8 ± 23.5
Samples of Group II (n= 24)
+ Collagen (2 lg/ml)
126.4 ± 19.7
Samples of Group III (n= 11)
+ Collagen (2 lg/ml)
71 ± 11.2
Data were presented as mean ± SD.
* P< 0.001 as compared with the resting group.
 P< 0.05 as compared with the collagen group.
 P< 0.001 as compared with the collagen group.
Antiaggregatory effect of midazolam on human platelets 7The current study attributed the antiplatelet effect of midazo-
lam to inhibition of thromboxane A2 formation.
In the current study, midazolam did not signiﬁcantly inhibit
the binding of FITC-triﬂavin to ﬁbrinogen receptor, signifying
that the antiplatelet effect of midazolam might not be caused
by preventing ﬁbrinogen from binding to its speciﬁc receptor
on the platelet membrane.
A Limitation to our study is that we did not repeat the tests
few hours or few days later to detect the remote effect of drug
on platelets.
5. Recommendations
We recommend that if the total dose of midazolam used dur-
ing sedation or anesthesia exceeded 7.2 mg, and/or if the pa-
tient was having a problem with his platelets (e.g. on chronic
antiplatelet therapy or bleeding tendencies); then, investiga-
tions should be performed to detect performance of midazo-
lam on platelets adhesions to ensure patient safety.6. Conclusion
The present study shows that midazolam dose-dependently
inhibits collagen-induced humanplatelet aggregation and inhib-
its thromboxaneA2 formation. Itwas also concluded that ﬁbrin-
ogen receptor (glycoprotein IIb–IIIa complex) on the platelet
surface membrane is not the site of action of midazolam.
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